SavedAdd your journal

Journals / OPUS Toplum Araştırmaları Dergisi / 2021 / Cilt: 4 - Sayı: 3

Euglycemic diabetic ketoacidosis due to empagliflozin; A Case Report

Empagliflozine Bağlı Gelişen Öglisemik Diyabetik Ketoasidoz; Olgu Sunumu

Pınar KARABACAK
Süleyman ÇELİK
Ayşe KÖSEM
Mustafa Soner ÖZCAN
Eyyüp Sabri ÖZDEN
Pages
87–89
Publication Date
2021-10-30
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Hyperglycemia (Blood glucose> 250 mg / dL), metabolic acidosis (pH

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Hyperglycemia (Blood glucose> 250 mg / dL), metabolic acidosis (pH
📊
Key Findings & Data:Hyperglycemia (Blood glucose> 250 mg / dL), metabolic acidosis (pH
💡
Conclusion & Impact:Hyperglycemia (Blood glucose> 250 mg / dL), metabolic acidosis (pH
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Empagliflozin · Öglisemik Diyabeti Ketoasidoz · Sodyum-glukoz ko-transporter 2 (SGLT-2) inhibitörleri

Abstract

Hyperglycemia (Blood glucose> 250 mg / dL), metabolic acidosis (pH

Özet

Hiperglisemi (Kan şekeri> 250 mg/dL), metabolik asidoz (pH

🔖

Cite This Article

KARABACAK, P., ÇELİK, S., KÖSEM, A., ÖZCAN, M. S., ÖZDEN, E. S. (2021). Euglycemic diabetic ketoacidosis due to empagliflozin; A Case Report. OPUS Toplum Araştırmaları Dergisi, Cilt: 4 - Sayı: 3, 87–89. https://ajindex.com/articles/856506

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas. Diabetes Res Clin Pract. 2019. 157;107843
  2. Nyenwe EA, Kitabchi AE. The evolution of diabetic ketoacidosis: An update of its etiology, pathogenesis and management. Metabolism. 2016. 65(4);507-21. doi: 10.1016/j.metabol.2015.12.007. Epub 2015 Dec 19. PMID: 26975543 3. Munro JF, Campbell IW, MacCuish AC, Duncan LC. Euglycaemic diabetic ketoacidosis. Br Med J 1973. 2(5866); 578–80
  3. Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018. 61(10):2108-2117
  4. Ray GM, Rodriguez C, Schulman SM, Sarangarm P, Bardack M, Bouchonville MF. (2019). Empagliflozin-induced Diabetic Ketoacidosis Unmasking a Type 1 Diabetes Diagnosis. Clin Pract Cases Emerg Med 2019. 3(2); 140
  5. Rawla P, Vellipuram AR, Bandaru SS, Pradeep R. J. Euglycemic diabetic ketoacidosis: a diagnostic and therapeutic dilemma. Endocrinol Diabetes Metab Case Rep 2017. 2017. pii: 17-0081. doi: 10.1530. EDM-17-0081
  6. Lucero P, Chapela S. Euglycemic Diabetic Ketoacidosis in the ICU: 3 Case Reports and Review of Literature. Case Rep Crit Care. 2018. 1;2018:1747850
  7. Danne T, Garg S, Peters AL, Buse JB, Mathieu C, Pettus JH et al. International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium–glucose cotransporter (SGLT) inhibitors. Diabetes Care 2019. 42(6);1147-54
  8. Tahrani A A, Bailey C J, Del Prato S, Barnett AH. Management of type 2 diabetes: new and future developments in treatment. The Lancet 2011. 378(9786); 182-97
  9. Drug Safety and Availability. FDA Drug Safety Communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. Available at: https://www.fda.gov/Drugs/DrugSafety/ ucm475463.htm. Accessed September 28, 2018
  10. Lund S, Solimando F, Kohler S, Zeller C, Kaspers, S. Effect of empagliflozin on diabetic ketoacidosis in patients with type 2 diabetes: pooled clinical trial data. Diabetologie und Stoffwechsel 2017. 12(01); 209
  11. Barski L, Eshkoli T, Brandstaetter E, Jotkowitz A. Euglycemic diabetic ketoacidosis. Eur J Intern Med. 2019 May;63:9-14
  12. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S et al. EMPA-